Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report.
OBJECTIVE
Despite the efficacy of antidepres-sants, depression can break through premenstrually. Oral contraceptive pills (OCPs) stabilize reproductive hormones and treat premenstrual dysphoric disorder. Management of depression that breaks through premenstrually has not been studied.


METHODS
Women taking antidepressants with successfully treated depression, except during the late luteal phase (Montgomery-Asberg Depression Rating Scale [MADRS] score >or= 15) and high late-luteal phase (Daily Rating of Severity of Problems scores) were randomly assigned to open-label ethinyl estradiol (EE) 30 mug/day plus drospirenone 3 mg/day (EE/DRSP) for 21 days and double-blinded treatment with EE 30 mug/day or placebo for days 22 through 28 of 2 cycles. Participants were recruited from community and psychiatry outpatient clinics and enrolled into this study in 2004-2005.


RESULTS
Of 25 subjects who received EE/DRSP (N = 12 with EE and N = 13 with placebo), 21 completed treatment. For study completers, premenstrual MADRS (p = .0019) and Daily Rating of Severity of Problems scores (p = .0001) improved significantly in both groups. Outcome did not differ between groups.


CONCLUSIONS
This study provides preliminary evidence that addition of EE/DRSP (+/- EE) to antidepressants may treat premenstrual breakthrough of depression. Stabilizing hormone levels with EE/DRSP may provide an important therapeutic option for women taking antidepressants whose symptoms break through premenstrually.
Joffe
Hadine
H
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. hjoffe@partners.org
Petrillo
Laura F
LF
Viguera
Adele C
AC
Gottshcall
Hannah
H
Soares
Claudio N
CN
Hall
Janet E
JE
Cohen
Lee S
LS
D000328:Adult; D000736:Androstenes / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use; D003276:Contraceptives, Oral / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000523:psychology*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D011374:Progesterone / Q000097:blood; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000736:Androstenes; D000928:Antidepressive Agents; D003276:Contraceptives, Oral; D004967:Estrogens; D000451:Mineralocorticoid Receptor Antagonists; D004997:Ethinyl Estradiol; D011374:Progesterone; D004958:Estradiol; C035144:drospirenone